Top Markets
Coin of the day
TTY Biopharm Company Limited TTY Biopharm Company Limited

TTY Biopharm Company Limited

4105
株式のランク #12139
TTY Biopharm Company Limited, along with its associated entities, specializes... TTY Biopharm Company Limited, along with its associated entities, specializes in the creation and distribution of pharmaceutical and chemical products across Taiwan and global markets. Its operations are structured into several key divisions: Oncology, Intensive Care, Healthcare, Export & CDMO, and an "Other" Business Unit. For anti-cancer and supportive therapies, the company markets a range of oncology medications under prominent brand names such as Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin, Tynen, Anazo, Folina, Thado, Andason, Ivic, Asadin, Leavdo, Painkyl, Megest, Episil, Otril, Zobonic, Yondelis, and Pemazyre. Addressing infectious diseases and influenza, TTY Biopharm supplies anti-infection drugs including Brosym, Colimycin, Cubicin, Lipo-AB, Agrippal, Cepiro, Flusine, Maxtam, Metacin, and Flucelvax. Furthermore, the firm offers various healthcare-related pharmaceuticals designed for the digestive system, osteoporosis, and metabolic conditions, marketed under brands like Algitab, Alginos, Alginos Fresh, Bio-Cal Plus, and Sulfin. Beyond pharmaceuticals, the company is also involved in distributing functional foods, conducting international trade (import/export), and engaging in investment ventures. Established in 1960, TTY Biopharm maintains its principal office in Taipei, Taiwan.
株価
$2.47
時価総額
$614.36M
変化(1日)
-0.13%
変化(1年)
-1.62%
TW
取引 TTY Biopharm Company Limited (4105)

カテゴリー

TTY Biopharm Company Limited(4105)の収益
Aug 2026 時点の収益 TTM: 0
TTY Biopharm Company Limited の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
TTY Biopharm Company Limited の収益履歴(2026 ~ 2026)
各年末の収益
収益 変化
提供された日付のデータは十分ではありません。